- Click here to download a free report overview (including the Table of Contents and a List of Exhibits)
- Click here to read the press release (which highlights some key findings about revenues, profits, and trends)
The 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors—our ninth edition—remains the most comprehensive tool for analyzing the economic and business realities of U.S. pharmaceutical distribution. This year's edition has been thoroughly updated, revised, and expanded. It contains the most current market and industry and data. The report is the only resource of its kind available anywhere.
See below for more info. Enjoy!
P.S. If you would like to pay by corporate purchase order or check, please email Tamra Feldman. If you preordered the report, you should have already received an email with download instructions. Please contact us if you did not receive the email.
WHAT'S THE DEAL, ADAM?
Twice a year, I spend my evenings and weekends writing two comprehensive, fact-based, and nonpartisan reports on drug channel economics. In some small way, I hope to make our world a better and smarter place.
Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more. So, you can find out what your customers and competitors are reading.
Here are some things to know about The 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors:
- Using DCI’s proprietary economic models, I delve into the business segments and underlying profitability of each public wholesaler: AmerisourceBergen, Cardinal Health, and McKesson. This information allows you to assess differences among the public wholesalers’ business organizations, strategies, and financial performance.
- I analyze how crucial healthcare trends will affect wholesalers and distributors, including: the outlook for brand-name drug prices, deflation of generic drug prices, vertical integration among healthcare providers, the profitability of specialty drugs and biosimilars, Amazon (of course), and much more.
- The nine chapters are self-contained and do not need to be read in order. (Really!) There are loads of internal hyperlinks to help you navigate the document and customize it to your specific interests and priorities.
- There are an astonishing 396 endnotes. Most of these notes have hyperlinks to original source materials, which I’m sure you’ll find useful. These source materials offer a handy way to build your knowledge base beyond what’s included in the full report.
- We offer the option to download an additional PowerPoint file with images of all 117 exhibits. This popular option helps you share the insights and data with others in your organization.
- I have reluctantly stripped out the goofy jokes and pop culture references. Sorry, SpongeBob fans!
P.S. We work hard to bring you great free content. Please respect our license terms if you decide to make a purchase. Thanks.